Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RAIN ONCOLOGY INC.

(RAIN)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-26 pm EST
10.00 USD   +5.15%
01/23Rain Oncology Inc. : Regulation FD Disclosure (form 8-K)
AQ
01/23Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology
AQ
01/23Rain Oncology Inc. Announces Phase 1 Clinical Data of Milademetan Publishes in Journal of Clinical Oncology
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Analyst Recommendations on RAIN ONCOLOGY INC.
01/23Mizuho Starts Rain Oncology at Buy With $18 Price Target
MT
01/06Lifesci Capital Starts Rain Therapeutics at Outperform With $17 Price Target
MT
01/05EF Hutton Initiates Rain Therapeutics at Buy With $16 Price Target
MT
2022Citigroup Adjusts Price Target on Rain Therapeutics to $29 From $30, Maintains Buy Rati..
MT
2022HC Wainwright Initiates Rain Therapeutics at Buy With $10 Price Target
MT
2022JonesTrading Initiates Rain Therapeutics at Buy With $17 Price Target
MT
2022Roth Capital Starts Rain Therapeutics at Buy With $16 Price Target
MT
2022Piper Sandler Adjusts Rain Therapeutics' Price Target to $12 From $26, Maintains Overwe..
MT
2022Oppenheimer Initiates Coverage on Rain Therapeutics With Outperform Rating, $15 Price T..
MT
2022Guggenheim Adjusts Price Target for Rain Therapeutics to $20 From $26, Maintains Buy Ra..
MT
2021Rain Therapeutics : Guggenheim Starts Rain Therapeutics at Buy With $2..
MT
2021Rain Therapeutics : Citigroup Starts Rain Therapeutics at Buy With $28..
MT
2021Rain Therapeutics : Goldman Sachs Starts Rain Therapeutics at Buy With..
MT
2021Rain Therapeutics : Piper Sandler Starts Rain Therapeutics at Overweig..
MT
Upcoming event on RAIN ONCOLOGY INC.